Scotiabank analyst George Farmer initiated coverage of Kura Oncology with a Sector Perform rating and $10.50 price target. The analyst rolled out coverage of the companies working on menin inhibition with two Outperforms and one Sector Perform.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on KURA:
- Kura Oncology to Report Second Quarter 2023 Financial Results
- Kura Oncology 3.03M share Spot Secondary priced at $11.50
- Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
- Kura Oncology falls almost 6% after announcing $100M common stock offering
- Kura Oncology Announces Commencement of Public Offering of Common Stock and Pre-Funded Warrants
